Navigation Links
Janssen and Johnson & Johnson to Provide Webcast Presentation on the Janssen Oncology Hematologic Malignancy Portfolio

NEW BRUNSWICK, N.J., Jan. 15, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focused on data from the Janssen Oncology hematologic malignancy portfolio for investors and other interested parties on Friday, January 15.

The pre-recorded webcast features Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head of Oncology for Janssen R&D, recapping key data presentations on DARZALEX™ (daratumumab) and IMBRUVICA® (ibrutinib) that were featured at the 2015 American Society of Hematology (ASH) Annual meeting. Dr. Lebowitz will also describe the development plans for these and other compounds in the Janssen Oncology hematologic malignancy portfolio.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at and clicking on "Webcasts/Presentations." The webcast duration is approximately 18 minutes and will be available through the end of February.

SOURCE Johnson & Johnson
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
2. ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection
3. Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections
4. Janssen to Showcase Growing Portfolio with More Than 40 Data Presentations at the 2015 American Society of Hematology (ASH) Annual Meeting
5. Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
6. Leitender Neurowissenschaftler bei Janssen in den Wissenschaftlichen Beirat des globalen Dementia Discovery Fund bestellt
7. Janssen Tackles Mental Health Stigma in New Healthy Minds Videos
8. U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
9. New Study by TSRI and Janssen Makes Major Advance Toward More Effective, Long-Lasting Flu Vaccine
10. Black Celebrities Come Out to Honor 2015 Heroes in the Struggle Honoring Jussie Smollett, Gregorio Millett, Vanessa Mills, and Janssen Therapeutics
11. Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
Post Your Comments:
(Date:10/12/2017)... 2017 West Pharmaceutical Services, Inc. ... injectable drug administration, today announced that it will release ... Thursday, October 26, 2017, and will follow with a ... at 9:00 a.m. Eastern Time. To participate on the ... conference ID is 94093362. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):